Abstract
Azathioprine (AZA) is commonly used in the treatment of atopic dermatitis (AD), but high discontinuation rates due to side effects and ineffectiveness are reported. Thioguanine reduces generation of potentially toxic metabolites, because it is primarily converted into the immunosuppressive metabolite 6-TGN by bypassing several rate-limiting metabolic steps. Thioguanine may be an alternative treatment option in patients with difficult to treat, severe AD who failed on AZA treatment. © 2019, Stichting Beheer Tijdschriften Dermatologie. All right reserved.
| Translated title of the contribution | Thioguanine for the treatment of atopic dermatitis |
|---|---|
| Original language | Dutch |
| Pages (from-to) | 25-27 |
| Number of pages | 3 |
| Journal | Nederlands Tijdschrift voor Dermatologie en Venereologie |
| Volume | 29 |
| Issue number | 4 |
| Publication status | Published - 2019 |